Company Overview and News
(Sept 20): Most Southeast Asian stock markets rose on Thursday, in line with Asian peers and overnight gains on Wall Street, while investors took heart as Sino-U.S. trade war pressures seemed to have eased.
GMALY SMPH ICT 4715 GMALF SPHXY SPHXF ICTEF SPHZF
Billionaire Enrique Razon Jr.’s International Container Terminal Services Inc. (ICTSI) is increasing its stake in Manila North Harbor Port Inc. to 50 percent—a deal that would make ICTSI the single largest shareholder in the country’s biggest domestic port.
ICT SVTMF PSKXF SMCP1 MPCIY SM ICTEF SMGBY SMGBF SMC2B SMIVY SMC2A SMC SMC2D SMC2C MPI MPCFF SMC2F SMC2E PHSXY PSE
HENRY SY, Sr. remains the country’s wealthiest man for the 11th straight year in Forbes Asia’s “Philippines’ 50 Richest” list, which reflected the economy’s overall volatility as many registered shifts in wealth from 2017.
ICT JGSMY GTCAP GTCXY SVTMF NIKL SMCP1 JGS SM ICTEF SECB SMGBF SMIVY SMC ALGGY SBS AGI JGSHF GMA7 SMGBY NIKAY SMC2B SMC2A SMC2D TECH SMC2C SMC2F SYBJF SMC2E ALGGF GNWKY LTG
International Container Terminal Services, Inc. (ICTSI) will be acquiring half of Habor Centre Port Terminal, Inc.’s Manila North Harbor Philippines, Inc. (MNHPI) after both parties agreed to the transaction last Wednesday, Sept. 5.
A subsidiary of International Container Terminal Services, Inc. (ICTSI) in Australia said it was able to handle larger capacity vessels at the Port of Melbourne. Victoria International Container Terminal (VICT) said it recently welcomed Orient Overseas Container Line (OOCL) Seoul — a 8,063-TEU (twenty-foot equivalent unit) capacity vessel. “VICT… is a highly automated terminal designed to meet the requirement for new capacity in Melbourne but more importantly to provide an efficient solution to catering for the larger vessel types now being progressively introduced into Australian container trade lanes,” ICTSI said in a statement.
The benchmark Philippine Stock Exchange index closed in positive territory Thursday even as regional equities saw mixed results on lingering trade tensions between the United States and China.
ICT GTCAP GTCXY SVTMF BDOUY SM ICTEF SECB BDOUF SMIVY MPCFF PHSXY PSE SPHXF SPHZF AYAAF PSKXF MPCIY AYAAY SMPH BDO MPI SPHXY SYBJF ALI
THE International Container Terminal Services, Inc. (ICTSI) and the Department of Transportation (DoTr) said the Cavite Gateway Terminal (CGT) may finally be used by end-September, months later its original target because of the three typhoons that affected the area in the past months.
SHARES snapped their five-day winning streak on Tuesday after investors resorted to profit taking ahead of the United States Federal Reserve’s meeting this week, even as those overseas remained predominantly buyers.
ICT GTCAP GTCXY GTMEY BDOUY ICTEF BDOUF JBFCF MPCFF PHSXY GTMEF PSE GLOPA UVRBF AYAAF DMC PSKXF MPCIY AYAAY JBFCY DMCIF UVRBY GLOPP DMCP BDO GLO MPI JFC URC DMCHY ALI
Local shares snapped their five-day winning streak on Tuesday, July 31, after investors resorted to profit taking ahead of the United States’ Federal Reserve’s meeting this week.
ICT GTMEY BDOUY ICTEF BDOUF JBFCF MPCFF PHSXY GTMEF PSE GLOPA UVRBF AYAAF DMC PSKXF MPCIY AYAAY JBFCY DMCIF UVRBY GLOPP DMCP BDO GLO MPI JFC URC DMCHY ALI
Over the last two years, the Department of Transportation (DOTr) has embarked on a series of steps to improve the lives of the commuters, motorists and the public, in general—crack down on corruption, secure funding for legacy infrastructure projects and even move its headquarters to Clark, Pampanga.
ICT MWP AYAAY GMRINFRA GMQRY MWIDE ICTEF ALI 532754 AYAAF
INTERNATIONAL Container Terminal Services, Inc. (ICTSI) said it has been chosen by the government of Sudan to handle the operations and management of the South Port Container Terminal (SPCT).
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET